VIRGINIA RETIREMENT SYSTEMS ET Al Trims Holdings in Globus Medical, Inc. $GMED

VIRGINIA RETIREMENT SYSTEMS ET Al decreased its holdings in Globus Medical, Inc. (NYSE:GMED) by 58.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 12,510 shares of the medical device company’s stock after selling 17,300 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Globus Medical were worth $1,092,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. William Blair Investment Management LLC increased its stake in Globus Medical by 17.2% in the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after purchasing an additional 414,134 shares during the period. ANTIPODES PARTNERS Ltd increased its stake in Globus Medical by 49,020.3% in the third quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock worth $51,034,000 after purchasing an additional 889,229 shares during the period. Foresight Group Ltd Liability Partnership increased its stake in Globus Medical by 160.7% in the third quarter. Foresight Group Ltd Liability Partnership now owns 421,541 shares of the medical device company’s stock worth $24,142,000 after purchasing an additional 259,870 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Globus Medical in the third quarter worth $539,000. Finally, Lightrock Netherlands B.V. increased its stake in Globus Medical by 6.2% in the third quarter. Lightrock Netherlands B.V. now owns 251,900 shares of the medical device company’s stock worth $14,426,000 after purchasing an additional 14,750 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 18.38% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Royal Bank Of Canada raised their price target on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Barclays raised their price target on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Truist Financial set a $115.00 price target on Globus Medical in a research note on Wednesday, February 25th. Finally, Needham & Company LLC raised their price target on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $106.36.

Globus Medical Trading Down 0.9%

Shares of Globus Medical stock opened at $76.52 on Friday. The firm has a market cap of $10.39 billion, a P/E ratio of 17.79, a P/E/G ratio of 1.58 and a beta of 1.00. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40. The stock’s fifty day moving average price is $87.78 and its 200-day moving average price is $87.08.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter last year, the firm posted $0.68 earnings per share. The business’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.